Fulcrum Therapeutics (NASDAQ:FULC) Major Shareholder Ra Capital Management, L.P. Sells 4,175,139 Shares of Stock

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) major shareholder Ra Capital Management, L.P. sold 4,175,139 shares of Fulcrum Therapeutics stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $13.98, for a total value of $58,368,443.22. Following the completion of the transaction, the insider directly owned 6,053,960 shares of the company’s stock, valued at approximately $84,634,360.80. This trade represents a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Fulcrum Therapeutics Stock Performance

Fulcrum Therapeutics stock opened at $13.80 on Thursday. Fulcrum Therapeutics, Inc. has a 52-week low of $2.32 and a 52-week high of $15.74. The stock’s 50 day moving average price is $9.65 and its two-hundred day moving average price is $8.03. The stock has a market capitalization of $746.86 million, a price-to-earnings ratio of -11.69 and a beta of 3.17.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Wednesday, October 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, equities research analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Algert Global LLC increased its position in Fulcrum Therapeutics by 6.0% in the first quarter. Algert Global LLC now owns 36,147 shares of the company’s stock worth $104,000 after buying an additional 2,030 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its stake in shares of Fulcrum Therapeutics by 26.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 12,943 shares of the company’s stock worth $89,000 after acquiring an additional 2,677 shares during the period. Strs Ohio grew its stake in shares of Fulcrum Therapeutics by 3.7% during the 3rd quarter. Strs Ohio now owns 77,900 shares of the company’s stock worth $717,000 after acquiring an additional 2,800 shares during the period. American Century Companies Inc. increased its holdings in Fulcrum Therapeutics by 2.6% in the 1st quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock worth $356,000 after acquiring an additional 3,100 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Fulcrum Therapeutics by 108.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 7,112 shares of the company’s stock valued at $65,000 after acquiring an additional 3,697 shares during the period. 89.83% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

FULC has been the topic of a number of research reports. The Goldman Sachs Group reaffirmed a “positive” rating on shares of Fulcrum Therapeutics in a research report on Monday. HC Wainwright raised their price objective on shares of Fulcrum Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a report on Wednesday, October 8th. Truist Financial set a $14.00 target price on shares of Fulcrum Therapeutics in a report on Monday, November 24th. Finally, Stifel Nicolaus set a $25.00 price objective on Fulcrum Therapeutics in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $18.50.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.